Skip to main content
logo
Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
17.75
-0.01 (-0.06%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Crescent Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-165.12-153.94-71.47
Depreciation & Amortization
0.210.08-
Asset Writedown & Restructuring Costs
80804
Stock-Based Compensation
14.8113.34.54
Other Operating Activities
0.392.40.01
Change in Accounts Receivable
--18-
Change in Accounts Payable
-3.49-529.31
Change in Unearned Revenue
3.124.16-
Change in Other Net Operating Assets
-0.825.478.54
Operating Cash Flow
-72.68-71.53-25.08
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.94-0.92-
Sale (Purchase) of Intangibles
-80-72-
Investing Cash Flow
-79.17-72.92-

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt Issued
--149.92
Net Debt Issued (Repaid)
--149.92
Issuance of Common Stock
177.89321.891.26
Repurchase of Common Stock
--0.18-
Other Financing Activities
-7.091.27-3.04
Financing Cash Flow
170.8322.98164.14

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
18.95178.53139.06

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-73.62-72.45-25.08
Free Cash Flow Growth
---
Free Cash Flow Margin
-619.52%-668.12%-
Free Cash Flow Per Share
-2.69-6.03-32.67
Levered Free Cash Flow
--153.7-
Unlevered Free Cash Flow
--152.33-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
-1.19-13.3737.85
SEC Filings: 10-K · 10-Q